About us Pricing ContactSubscribe

C

Chengping Hu

Central South UniversityORCID https://orcid.org/0000-0002-1285-8579

h-index

—

Publications

—

Citations

—

i10-index

—

Impact (2-yr)

—

Top Publications

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

The Lancet Oncology20114,075 citations

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

The Lancet Oncology20141,963 citations

Chengping Hu · Scinovex